AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
==== Avonex ==== Avonex was approved in the US in 1996, and in the European Union in 1997, and is registered in more than 80 countries worldwide. It is the leading MS therapy in the US, with around 40% of the overall market, and in the European Union, with around 30% of the overall market. It is produced by the Biogen biotechnology company, originally under competition protection in the US under the Orphan Drug Act. Avonex is sold in three formulations, a lyophilized powder requiring reconstitution, a pre-mixed liquid syringe kit, and a pen; it is administered via intramuscular injection.
=== Amino acid deficiency detection === At low concentration of amino acid, GCN2 is activated due to the increase level of uncharged tRNA molecules. Uncharged tRNA activates GCN2 due to the displacement of the protein kinase moiety from a bipartite tRNA-binding domain. Activated GCN2 phosphorylates itself and eIF2α, it triggers a transcriptional and translational response to restore amino acid homeostasis by affecting the utilization, acquisition, and mobilization of amino acid in an organism.
2nd Lieutenant Tanimoto Kikuo an intelligence officer who was originally supposed to remain behind in Indonesia, but linked up with the 34th Brigade to try to get home, only to end up as an instructor at the Quảng Ngãi Military Academy until 1954. 2nd Lieutenant Nakahara Mitsunobu – an intelligence officer of the 34th Independent Mixed Brigade; became a decorated soldier in the Việt Minh forces, and later an instructor at the Quảng Ngãi Military Academy.
Sources: en.wikipedia.org
== Enzyme mechanism == The main reaction is an SN2 displacement of the halogen for a hydroxyl group derived from water. To begin, aspartate 124 is perfectly aligned with the substrate. It will drive off the halogen and form an ester functionality carbon-oxygen bond. Following this displacement is a hydrolysis reaction by utilizing the imidazole ring of histidine 289 as the general base. This will deprotonate water, form a tetrahedral intermediate at the original ester, and create an imidazolium cation at histidine. The final step is beta-elimination. With a newly formed imidazolium cation ready to be an acid, aspartate 124 reverts to its original acidic state and breaks the ester linkage, as well as deprotonating histidine 289. The alcohol is eliminated and the halogen is now a free anion. Also taking place in a facilitating role are tryptophan groups in the periphery of the active site. These residues provide hydrogen bond donor groups to the chloride as it begins to undergo the SN2 reaction and become an anion. A second tryptophan also provides rigidity through a stable peptide bond to aspartate 124. It holds the beta-carbon oxygen in place so that it’s in prime position to make the ester linkage.
== Background == In 2012, Mali experienced a deep political and security crisis due to the insurgency in its northern regions. A military coup in Bamako and the rise of armed Tuareg groups, such as the National Movement for the Liberation of Azawad (MNLA) and jihadist elements, destabilised the region further. By 2013, the Malian government, supported by French forces under Operation Serval, as well as troops from Chad and other African nations, managed to recapture much of the north from jihadist control. However, the MNLA had taken advantage of the power vacuum left by retreating jihadists to regain control over key cities in northern Mali, particularly Kidal, a strategic town in the region of Azawad. In this context, tensions escalated between the MNLA and the Malian government over control of Kidal and the organisation of the upcoming presidential elections. While initially refusing to allow elections in Kidal, the MNLA eventually agreed to permit them in July 2013, provided that United Nations troops secured the voting process across Azawad. The Malian government, however, insisted that its own military forces must be present in Kidal to oversee security, which led to further friction between the two parties. By June 2013, tensions boiled over when the MNLA arrested 180 individuals in Kidal, accusing them of being Malian spies or infiltrators. Accusations of violence, pillaging, and ethnic targeting by the MNLA against black populations such as the Songhai, Peulh, and Bella people, were made.
== History == Gepirone was developed by Bristol-Myers Squibb in 1986, but was out-licensed to Fabre-Kramer in 1993. The FDA rejected approval for gepirone in 2002 and 2004. It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2009. However, in 2012 it once again failed to convince the FDA of its qualities for treating anxiety and depression. In December 2015, the FDA once again gave gepirone a negative review for depression due to concerns of efficacy. However, in March 2016, the FDA reversed its decision and gave gepirone ER a positive review. Gepirone ER was finally approved for the treatment of major depressive disorder in the United States in September 2023. A 2026 scientific paper discussed the FDA's decision process and cricitised the approval and subsequent labeling of the drug.
Sources: en.wikipedia.org
Roughly speaking, high sequence identity suggests that the sequences in question have a comparatively young most recent common ancestor, while low identity suggests that the divergence is more ancient. This approximation, which reflects the "molecular clock" hypothesis that a roughly constant rate of evolutionary change can be used to extrapolate the elapsed time since two genes first diverged (that is, the coalescence time), assumes that the effects of mutation and selection are constant across sequence lineages. Therefore, it does not account for possible differences among organisms or species in the rates of DNA repair or the possible functional conservation of specific regions in a sequence. (In the case of nucleotide sequences, the molecular clock hypothesis in its most basic form also discounts the difference in acceptance rates between silent mutations that do not alter the meaning of a given codon and other mutations that result in a different amino acid being incorporated into the protein.) More statistically accurate methods allow the evolutionary rate on each branch of the phylogenetic tree to vary, thus producing better estimates of coalescence times for genes.
Heseltine also favoured European cooperation in defence procurement, feeling that this allowed Europe to compete with US firms which receive huge orders from The Pentagon. Crick argues that his experience of Concorde in the early 1970s should have warned him that such multinational ventures are problematic and, because of the political capital invested, hard to cancel when things go wrong. Heseltine played an important role in persuading West German defence minister Manfred Wörner to back the joint Anglo-German-Spanish-Italian Eurofighter, and contrary to the wishes of Thatcher (and previous defence secretary John Nott) who preferred an American or British fighter. Cabinet refused to allow a loosening of the specifications to allow French company Dassault to become involved in the consortium. Agreement was reached at Turin in August 1985. Heseltine also sold 132 Tornados for £4bn to Saudi Arabia later in 1985, accepting oil instead of cash (to the displeasure of Peter Walker, Energy Secretary) so that they would buy British rather than US aircraft. This later formed part of the controversial Al-Yamamah arms deal, the main part of which was signed in 1988.
== Treatment == Currently this sub-type of muscular dystrophy has no cure and no definitive treatment exists. Treatment offers preventative tactics to delay muscle breakdown and increase life expectancy. Stretching and physical therapy can increase mobility. Treatment also includes correcting skeletal abnormalities through orthopedic surgery and other orthopedic techniques. Antiepileptic medication is administered to help prevent seizures. ACE inhibitors and beta blockers help treat heart conditions, and respiratory assistance is more than likely needed at some point for the affected individual.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.